Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

NCT06909253 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG: Ravulizumab

Sponsor

AstraZeneca